Attention-deficit/hyperactivity disorder, better known as ADHD, is one of the most common neurodevelopmental conditions in the world. It affects both children and adults and can have a major impact on daily life.
People with ADHD often struggle with paying attention, staying organized, controlling impulsive actions, and managing high levels of activity. These challenges can affect school performance, work productivity, relationships, and overall quality of life.
Although ADHD has been recognized for many years, treating the condition is not always straightforward. Several medications are available, and stimulant drugs are among the most commonly prescribed treatments. These medicines can help many people improve focus and reduce impulsive behavior. However, they do not work for everyone.
Some people experience unpleasant side effects such as trouble sleeping, headaches, reduced appetite, anxiety, or increased blood pressure.
Others may not respond well to treatment at all. Researchers estimate that about one in four people with ADHD do not receive enough benefit from currently available medications. Because of these limitations, scientists continue searching for new treatment options that are both effective and safe.
A new international study has now uncovered an unexpected possibility. Researchers from the University of Surrey and several collaborating institutions have found evidence that a common blood pressure medication called amlodipine may help reduce symptoms associated with ADHD.
The study was published in the scientific journal Neuropsychopharmacology and offers a fresh approach to developing treatments for the condition. Rather than creating an entirely new drug from scratch, the researchers explored whether an existing medication could be used for a completely different purpose. This strategy is known as drug repurposing.
Drug repurposing has become increasingly popular in medical research because it can significantly shorten the time needed to develop new treatments. Since the safety of approved medications is already well understood, researchers can often move more quickly toward clinical testing for new uses.
Amlodipine is one of the most widely prescribed medications for high blood pressure. Millions of people around the world have taken it safely for many years. It belongs to a group of medications called calcium channel blockers, which help relax blood vessels and improve blood flow.
The research team wanted to determine whether amlodipine might also influence brain processes involved in ADHD. To investigate this possibility, they conducted a series of experiments using animal models commonly used in behavioral research.
The first tests involved specially bred rats that display behaviors similar to some symptoms seen in people with ADHD. These animals tend to be unusually active and impulsive, making them useful for studying potential treatments.
The scientists tested five different medications. Among all the drugs examined, amlodipine stood out as the only one that produced a clear and significant effect. The medication noticeably reduced hyperactive behavior in the rats.
To strengthen their findings, the researchers performed additional experiments using zebrafish. Although these small fish may seem like an unusual choice, they are widely used in scientific research because they share many important genetic and biological features with humans.
Their nervous systems allow researchers to study brain function and behavior in ways that can provide valuable insights into human conditions.
The zebrafish experiments produced similar results. Amlodipine reduced hyperactivity and also appeared to improve impulsive behavior. Since impulsivity is one of the core symptoms of ADHD, this finding was particularly encouraging.
One of the most important discoveries involved the drug’s ability to reach the brain. The brain is protected by a highly selective defense system called the blood-brain barrier. This barrier prevents many substances circulating in the bloodstream from entering brain tissue. For a medication to directly affect brain function, it generally needs to cross this protective barrier.
The researchers demonstrated that amlodipine can pass through the blood-brain barrier and enter the brain. This was an important finding because it provided a biological explanation for how the medication might influence ADHD-related symptoms.
According to the researchers, this was the first clear evidence showing that amlodipine can cross into the brain in this way.
The team then examined human genetic data to better understand the potential connection between ADHD and the drug’s biological effects.
Their analysis revealed that ADHD is associated with specific calcium channels found in brain cells. These channels play an important role in communication between neurons, allowing electrical signals to travel through brain networks.
Interestingly, amlodipine targets the same calcium channels identified in the genetic analysis. This suggests that the medication may help regulate abnormal signaling patterns that contribute to ADHD symptoms.
The researchers also explored real-world patient data from across the United Kingdom. They found that individuals who were already taking amlodipine for blood pressure treatment tended to report fewer mood swings and less risky behavior compared with people who were not taking the medication.
Although these observations do not prove cause and effect, they provide additional support for the idea that amlodipine may influence behavior and emotional regulation.
Dr. Matthew Parker from the University of Surrey, one of the study’s authors, explained that the findings are exciting because they could accelerate the development of new ADHD treatments.
Since amlodipine is already approved and widely prescribed, researchers may be able to move more quickly into human clinical trials than would be possible with a completely new drug.
This could be particularly valuable for people whose symptoms are not adequately controlled by existing medications. Having additional treatment choices would allow doctors to better tailor care to individual needs.
Despite the promising results, the researchers emphasize that much more work remains to be done. The current findings are based largely on animal studies, genetic analyses, and observational patient data.
Carefully designed clinical trials involving people with ADHD will be necessary to determine whether amlodipine is truly effective and safe as an ADHD treatment.
Nevertheless, the study highlights the potential benefits of looking at familiar medicines from new perspectives. Sometimes drugs developed for one purpose may hold unexpected value in completely different areas of medicine.
If future clinical trials confirm these early findings, a medication already found in medicine cabinets around the world could become a valuable new tool for helping people manage ADHD symptoms. Such a development could improve treatment options, expand access to care, and offer hope to millions of individuals living with this challenging condition.
If you care about high blood pressure, please read studies about potatoes and high blood pressure, and top 10 choices for a blood pressure-friendly diet
For more information about high blood pressure, please see recent studies about impact of vitamins on high blood pressure you need to know, and the powerful link between high blood pressure and a potassium-rich diet.
The study was published in the journal Neuropsychopharmacology.
Copyright © 2026 Knowridge Science Report. All rights reserved.
